HCW Biologics (HCWB) shares were sharply higher in Monday's premarket session after it said it received US Food and Drug Administration clearance to launch a phase 1 trial to evaluate HCW9302 for the treatment of moderate-to-severe alopecia areata.
The company said the goal of the trial is to determine a safe dose of HCW9302 that effectively increases regulatory T cell activity in patients.
"Once we achieve this objective, we will rapidly expand clinical development of HCW9302 in phase 2 studies in patients with other autoimmune diseases and inflammatory conditions," Chief Executive Hing Wong said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。